KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBIT (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed EBIT for 13 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 62.03% to -$5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$38.2 million through Dec 2025, up 50.0% year-over-year, with the annual reading at -$38.2 million for FY2025, 50.0% up from the prior year.
  • EBIT hit -$5.3 million in Q4 2025 for Arbutus Biopharma, up from -$8.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.5 million in Q2 2025 to a low of -$25.7 million in Q1 2025.
  • Historically, EBIT has averaged -$16.6 million across 5 years, with a median of -$18.4 million in 2021.
  • Biggest five-year swings in EBIT: crashed 58.68% in 2023 and later skyrocketed 106.89% in 2025.
  • Year by year, EBIT stood at -$20.8 million in 2021, then dropped by 8.49% to -$22.6 million in 2022, then increased by 8.04% to -$20.7 million in 2023, then skyrocketed by 32.84% to -$13.9 million in 2024, then skyrocketed by 62.03% to -$5.3 million in 2025.
  • Business Quant data shows EBIT for ABUS at -$5.3 million in Q4 2025, -$8.7 million in Q3 2025, and $1.5 million in Q2 2025.